Human Papillomavirus Testing and Size of CIN3: Implications for the Risk of Microinvasive Cervical Carcinoma
Mario Preti(St. Anna Hospital), Lauro Bucchi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Raffaella Rizzolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Federica Zamagni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Guglielmo Ronco(Piedmont Reference Center for Epidemiology and Cancer Prevention), Fulvio Borella(Ospedale Sant'Anna), Silvano Costa, Christine Bergeron(Hôpital de Vaugirard-Gabriel Pallez), Silvia Mancini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Pedro Vieira-Baptista(Universidade do Porto), Laura De Marco(Piedmont Reference Center for Epidemiology and Cancer Prevention), Maria Kyrgiou(Imperial College Healthcare NHS Trust), Daniele Tota(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Luigia Macrì(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Annibale Biggeri(University of Padua), Stefano Cosma(St. Anna Hospital), Niccolò Gallio(Ospedale Sant'Anna), Murat Gultekin(Hacettepe University), Paola Armaroli(Piedmont Reference Center for Epidemiology and Cancer Prevention)
Cited by 1
Related Papers
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
|International Journal of Cancer|2006|417
Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test
|JNCI Journal of the National Cancer Institute|2008|307
All-cause, cardiovascular disease and cancer mortality in the population of a large Italian area contaminated by perfluoroalkyl and polyfluoroalkyl substances (1980–2018)
|Environmental Health|2024|59
Effects of Attendance to an Organized Fecal Immunochemical Test Screening Program on the Risk of Colorectal Cancer: An Observational Cohort Study
|Clinical Gastroenterology and Hepatology|2022|31